The global Bevacizumab Monoclonal Antibody Biosimilar market was valued at US$ 1379.8 million in 2022 and is projected to reach US$ 484.9 million by 2029, at a CAGR of -13.9% during the forecast period. The influence of COVID-19 and the Russia-Ukrai…Read More>>
The global Enbrel (Etanercept) Biosimilar market was valued at US$ 1283.1 million in 2022 and is projected to reach US$ 1732.5 million by 2029, at a CAGR of 4.4% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were c…Read More>>
The global Enbrel (Etanercept) and Biosimilar market was valued at US$ 6533.8 million in 2022 and is projected to reach US$ 8122.5 million by 2029, at a CAGR of 3.2% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War we…Read More>>
The global Epogen and Biosimilar market was valued at US$ 735.7 million in 2022 and is projected to reach US$ 593.8 million by 2029, at a CAGR of -3.0% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered …Read More>>
The global Herceptin (Trastuzumab) and Biosimilar market was valued at US$ 4642.6 million in 2022 and is projected to reach US$ 6357.7 million by 2029, at a CAGR of 4.6% during the forecast period. The influence of COVID-19 and the Russia-Ukraine Wa…Read More>>
The global Lucentis (Ranibizumab) and Biosimilar market was valued at US$ 1156.5 million in 2022 and is projected to reach US$ 971.5 million by 2029, at a CAGR of -2.5% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War…Read More>>
The global Neulasta (Pegfilgrastim) and Biosimilar market was valued at US$ 2501.4 million in 2022 and is projected to reach US$ 3816.3 million by 2029, at a CAGR of 6.2% during the forecast period. The influence of COVID-19 and the Russia-Ukraine W…Read More>>
The global Remicade (Infliximab) and Biosimilar market was valued at US$ 2623.8 million in 2022 and is projected to reach US$ 3781.3 million by 2029, at a CAGR of 5.4% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War …Read More>>
The global Remicade (Infliximab) Monoclonal Antibody market was valued at US$ 2623.8 million in 2022 and is projected to reach US$ 3781.3 million by 2029, at a CAGR of 5.4% during the forecast period. The influence of COVID-19 and the Russia-Ukraine…Read More>>
The global Rituxan (Rituximab) Monoclonal Antibody market was valued at US$ 4244.4 million in 2022 and is projected to reach US$ 5345.4 million by 2029, at a CAGR of 3.3% during the forecast period. The influence of COVID-19 and the Russia-Ukraine W…Read More>>
